ME03476B - Nefukozilisana anti-fgfr2iiib antitijela - Google Patents

Nefukozilisana anti-fgfr2iiib antitijela

Info

Publication number
ME03476B
ME03476B MEP-2019-142A MEP2019142A ME03476B ME 03476 B ME03476 B ME 03476B ME P2019142 A MEP2019142 A ME P2019142A ME 03476 B ME03476 B ME 03476B
Authority
ME
Montenegro
Prior art keywords
afucosylated anti
fgfr2iiib antibodies
fgfr2iiib
antibodies
afucosylated
Prior art date
Application number
MEP-2019-142A
Other languages
German (de)
English (en)
French (fr)
Inventor
Thomas Harding
Kristen Pierce
Namrata Patil
Thomas Brennan
Julie Hambleton
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51358085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03476(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of ME03476B publication Critical patent/ME03476B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-2019-142A 2013-08-01 2014-07-31 Nefukozilisana anti-fgfr2iiib antitijela ME03476B (me)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361861198P 2013-08-01 2013-08-01
US201361901732P 2013-11-08 2013-11-08
US201461933632P 2014-01-30 2014-01-30
PCT/US2014/049008 WO2015017600A1 (en) 2013-08-01 2014-07-31 Afucosylated anti-fgfr2iiib antibodies
EP14752705.5A EP3027651B1 (en) 2013-08-01 2014-07-31 Afucosylated anti-fgfr2iiib antibodies

Publications (1)

Publication Number Publication Date
ME03476B true ME03476B (me) 2020-01-20

Family

ID=51358085

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-142A ME03476B (me) 2013-08-01 2014-07-31 Nefukozilisana anti-fgfr2iiib antitijela

Country Status (30)

Country Link
US (5) US20150050273A1 (me)
EP (3) EP3027651B1 (me)
JP (5) JP6860342B2 (me)
KR (3) KR20250099279A (me)
CN (2) CN112225810B (me)
AU (4) AU2014296174B2 (me)
CA (1) CA2915665C (me)
CL (2) CL2016000221A1 (me)
CY (2) CY1121517T1 (me)
DK (2) DK3027651T3 (me)
ES (2) ES2913291T3 (me)
HR (1) HRP20190502T1 (me)
HU (2) HUE043815T2 (me)
IL (1) IL243409B (me)
LT (2) LT3027651T (me)
ME (1) ME03476B (me)
MX (2) MX374785B (me)
MY (1) MY184628A (me)
NZ (1) NZ715201A (me)
PE (2) PE20210949A1 (me)
PH (3) PH12019501393B1 (me)
PL (2) PL3708583T3 (me)
PT (2) PT3708583T (me)
RS (1) RS58719B1 (me)
RU (2) RU2740714C2 (me)
SG (1) SG11201600767UA (me)
SI (2) SI3708583T1 (me)
TW (2) TWI679021B (me)
WO (1) WO2015017600A1 (me)
ZA (1) ZA201603218B (me)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ715201A (en) 2013-08-01 2021-12-24 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
CA2926306C (en) * 2013-11-05 2022-12-06 F. Hoffmann-La Roche Ag A method for determining the total amount and/or concentration of an analyte in a sample
US10881734B2 (en) 2015-04-20 2021-01-05 Daiichi Sankyo Company, Limited Monoclonal antibodies to human fibroblast growth factor receptor 2 (HFGFR2) and methods of use thereof
EP3380523A1 (en) * 2015-11-23 2018-10-03 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
EP4650004A2 (en) * 2017-05-16 2025-11-19 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
EP3625256A1 (en) 2017-05-19 2020-03-25 The U.S.A. as represented by the Secretary, Department of Health and Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
MA49950A (fr) 2017-08-25 2020-07-01 Five Prime Therapeutics Inc Anticorps anti-b7-h4 et leurs procédés d'utilisation
SG11202007821WA (en) 2018-02-21 2020-09-29 Five Prime Therapeutics Inc B7-h4 antibody formulations
SG11202007820QA (en) 2018-02-21 2020-09-29 Five Prime Therapeutics Inc B7-h4 antibody dosing regimens
JP2021516051A (ja) 2018-03-02 2021-07-01 ファイブ プライム セラピューティクス， インコーポレイテッド Ｂ７−ｈ４抗体及びその使用方法
AU2019355995A1 (en) * 2018-10-05 2021-04-08 Five Prime Therapeutics, Inc. Anti-FGFR2 antibody formulations
MA53911A (fr) 2018-10-15 2022-01-19 Five Prime Therapeutics Inc Polythérapie contre le cancer
CA3160810A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
JP7692419B2 (ja) * 2019-12-24 2025-06-13 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド 新規抗ＦＧＦＲ２ｂ抗体
KR20220119143A (ko) * 2019-12-24 2022-08-26 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 신규한 항fgfr2b 항체
CN115768465A (zh) 2020-03-06 2023-03-07 Ona疗法有限公司 抗cd36抗体及其治疗癌症的用途
NZ797493A (en) * 2020-10-22 2024-05-31 Regeneron Pharma Anti-fgfr2 antibodies and methods of use thereof
WO2022143728A1 (zh) * 2020-12-29 2022-07-07 深圳福沃药业有限公司 抗fgfr2抗体及其用途
MX2024001415A (es) 2021-07-30 2024-02-27 Ona Therapeutics S L Anticuerpos anti-cd36 y su uso para tratar el cancer.
US20250277041A1 (en) * 2021-10-08 2025-09-04 Shenzhen Forward Pharmaceuticals Co., Limited Anti-fgfr2 adcc enhanced antibody and use thereof
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
AU2023350283A1 (en) * 2022-09-30 2025-05-22 3H Pharmaceuticals Co., Ltd. Anti-fgfr2b antibodies and uses thereof
CN117917435A (zh) * 2022-10-21 2024-04-23 北京天广实生物技术股份有限公司 结合fgfr2b的抗体及其用途
CN120677176A (zh) * 2022-12-28 2025-09-19 苏州创胜医药集团有限公司 抗fgfr2b抗体及其用途
CN118852431A (zh) * 2023-04-28 2024-10-29 武汉人福创新药物研发中心有限公司 抗FGFR2b单抗
TW202540177A (zh) * 2023-11-14 2025-10-16 大陸商蘇州創勝醫藥集團有限公司 抗－ＦＧＦＲ２ｂ免疫偶聯物及其於治療癌症的用途
WO2025130860A1 (zh) * 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体及其应用
WO2025232811A1 (zh) * 2024-05-09 2025-11-13 正大天晴药业集团股份有限公司 靶向成纤维细胞生长因子受体2IIIb的抗体及其应用

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1991000916A2 (en) 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU3494397A (en) 1996-06-18 1998-01-07 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Fibroblast growth factor receptor activating gene i and related compositions and methods
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
EP1125584A4 (en) 1998-10-30 2005-01-12 Takeda Chemical Industries Ltd PREPARATIONS CONTAINING BETACELLULIN PROTEIN
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2601882T5 (es) 1999-04-09 2021-06-07 Kyowa Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
HK1045700B (zh) 1999-04-28 2007-07-27 德克萨斯大学董事会 用於通过选择性抑制vegf来治疗癌症的组合物和方法
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
HU231090B1 (hu) 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
AU2002329540A1 (en) 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
CN101357943A (zh) * 2001-10-25 2009-02-04 杰南技术公司 糖蛋白组合物
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
DK1469878T3 (da) 2002-01-31 2011-07-18 Max Planck Gesellschaft FGFR agonister
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
CA2481656A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
KR100493460B1 (ko) 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK2289936T3 (en) 2002-12-16 2017-07-31 Genentech Inc IMMUNGLOBULIN VARIATIONS AND APPLICATIONS THEREOF
RU2337107C2 (ru) * 2003-05-02 2008-10-27 Ксенкор, Инк. ОПТИМИЗИРОВАННЫЕ Fc-ВАРИАНТЫ, ИМЕЮЩИЕ ИЗМЕНЕННОЕ СВЯЗЫВАНИЕ С FcγR, И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
WO2005035586A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
WO2005035778A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
CA2762955A1 (en) * 2003-10-16 2005-04-28 Imclone Llc Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
US8268582B2 (en) 2003-10-22 2012-09-18 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
DK2380910T3 (en) 2003-11-05 2015-10-19 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
WO2005066211A2 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
US7872016B2 (en) 2004-05-25 2011-01-18 Yale University Method for treating skeletal disorders resulting from FGFR malfunction
US20080286834A1 (en) 2005-01-27 2008-11-20 Robert Forgan Halenbeck Leader Sequences For Directing Secretion of Polypeptides and Methods For Production Thereof
US8207303B2 (en) * 2005-02-18 2012-06-26 Medarex, Inc. Monoclonal antibodies against CD30 lacking in fucosyl residues
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
US7890267B2 (en) 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
EP2018442A2 (en) 2006-05-12 2009-01-28 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
CA2655246A1 (en) * 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
EP2046384A4 (en) 2006-06-15 2009-12-02 Fibron Ltd ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME
AR062223A1 (es) * 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
AU2007305443B2 (en) 2006-09-29 2012-08-23 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP5570218B2 (ja) 2006-11-03 2014-08-13 ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆｇｆｒ４抗体
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008079849A2 (en) 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
KR101578940B1 (ko) 2007-01-24 2015-12-18 교와 핫꼬 기린 가부시키가이샤 이펙터 활성이 증강된 유전자 재조합 항체 조성물
AU2008230880B2 (en) 2007-03-23 2014-04-24 The Translational Genomics Research Institute Method of diagnosing, classifying and treating endometrial cancer and precancer
WO2008121876A2 (en) * 2007-03-28 2008-10-09 Biogen Idec Inc. Non-fucosylated antibodies
EP2205277B1 (en) 2007-10-22 2017-07-26 Genmab A/S Novel antibody therapies
WO2012021841A2 (en) 2010-08-12 2012-02-16 Attogen Inc. Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
EP2259636B1 (en) 2008-03-26 2018-11-14 NEC Corporation Radio resource control method, radio station device, recording medium containing radio station control program, and radio communication system
CA2727247A1 (en) * 2008-06-10 2009-12-17 University Of Southern California Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
LT3290052T (lt) 2008-11-07 2020-02-25 Galaxy Biotech, Llc Monokloniniai antikūnai fibroblastų augimo faktoriaus receptoriui 2
US20120301482A1 (en) 2009-08-25 2012-11-29 National Jewish Health Methods and compositions for treatment of lung injury
PL2486141T3 (pl) * 2009-10-07 2018-07-31 Macrogenics, Inc. Polipeptydy zawierające regiony fc i mające w wyniku zmian w zakresie fukozylacji ulepszoną funkcję efektorową, i sposoby zastosowania tych polipeptydów
US8664365B2 (en) * 2009-10-14 2014-03-04 Kalobios Pharmaceuticals, Inc. Antibodies to EphA3
CA2786276A1 (en) 2010-01-14 2011-07-21 Yale University Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
US9140689B2 (en) 2010-03-14 2015-09-22 Translational Genomics Research Institute Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
JP2013529076A (ja) 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｆｇｆｒ２抗体
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
EP3219731A1 (en) * 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
KR20140114826A (ko) 2011-12-14 2014-09-29 시애틀 지네틱스, 인크. Fgfr 항체 약물 콘주게이트 (adcs) 및 그의 용도
PL2831110T3 (pl) * 2012-03-30 2018-11-30 The Regents Of The University Of California Terapia anty-EMP2 zmniejsza ilość rakowych komórek macierzystych
CA2870126C (en) 2012-04-09 2020-10-27 Daiichi Sankyo Company, Limited Anti-fgfr2 antibody
US9254288B2 (en) 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
SG10201700698WA (en) 2012-05-15 2017-02-27 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
EP2871236A4 (en) 2012-07-05 2016-03-09 Nat Cancer Ct FGFR2 fusion
WO2014089193A1 (en) 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9415118B2 (en) 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
SG11201508878WA (en) 2013-05-01 2015-11-27 Five Prime Therapeutics Inc Methods of treating cancer
JP6696896B2 (ja) 2013-06-13 2020-05-20 ユニバーシティ オブ サウス オーストラリアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈ Ａｕｓｔｒａｌｉａ 前立腺癌を検出する方法
NZ715201A (en) * 2013-08-01 2021-12-24 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US20170175197A1 (en) 2014-01-29 2017-06-22 Caris Mpi, Inc. Molecular profiling of immune modulators
KR20170080675A (ko) 2014-11-05 2017-07-10 제넨테크, 인크. 항-fgfr2/3 항체 및 이의 이용 방법
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3380523A1 (en) 2015-11-23 2018-10-03 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
EP4650004A2 (en) 2017-05-16 2025-11-19 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment

Also Published As

Publication number Publication date
RU2016106101A (ru) 2017-09-06
KR20250099279A (ko) 2025-07-01
CA2915665C (en) 2020-07-28
HK1220211A1 (en) 2017-04-28
AU2021245169A1 (en) 2021-11-04
ES2719103T3 (es) 2019-07-08
CA2915665A1 (en) 2015-02-05
TWI679021B (zh) 2019-12-11
AU2019206039A1 (en) 2019-08-01
BR112015032789A2 (pt) 2017-11-07
RU2019125027A (ru) 2019-08-19
EP3027651B1 (en) 2019-02-27
KR102825701B1 (ko) 2025-06-27
MX374785B (es) 2025-03-06
US20160339100A1 (en) 2016-11-24
HRP20190502T1 (hr) 2019-05-03
RU2698061C2 (ru) 2019-08-21
PH12019501393B1 (en) 2022-09-07
US10172937B2 (en) 2019-01-08
JP2016527273A (ja) 2016-09-08
PH12016500137A1 (en) 2016-04-18
JP2023018049A (ja) 2023-02-07
CN112225810A (zh) 2021-01-15
KR102516152B1 (ko) 2023-03-31
US12465636B2 (en) 2025-11-11
EP3708583B1 (en) 2022-03-02
SI3027651T1 (sl) 2019-05-31
JP2020040955A (ja) 2020-03-19
PH12019501393A1 (en) 2020-09-14
JP7183136B2 (ja) 2022-12-05
MX2016001236A (es) 2016-05-24
SI3708583T1 (sl) 2022-05-31
SG11201600767UA (en) 2016-03-30
PE20160190A1 (es) 2016-04-28
EP3708583A1 (en) 2020-09-16
US11235059B2 (en) 2022-02-01
TWI633120B (zh) 2018-08-21
US20150050273A1 (en) 2015-02-19
KR20160030578A (ko) 2016-03-18
PH12016500137B1 (en) 2019-12-04
ES2913291T3 (es) 2022-06-01
US20220168416A1 (en) 2022-06-02
JP2022078080A (ja) 2022-05-24
RU2740714C2 (ru) 2021-01-20
CY1121517T1 (el) 2020-05-29
TW201536804A (zh) 2015-10-01
RS58719B1 (sr) 2019-06-28
WO2015017600A1 (en) 2015-02-05
CL2018002291A1 (es) 2018-09-14
HUE043815T2 (hu) 2019-09-30
DK3708583T3 (da) 2022-05-16
AU2019206039B2 (en) 2021-07-08
US20250269016A1 (en) 2025-08-28
NZ715201A (en) 2021-12-24
PE20210949A1 (es) 2021-05-24
JP6860342B2 (ja) 2021-04-14
PT3027651T (pt) 2019-05-31
CN105452296B (zh) 2020-09-25
LT3027651T (lt) 2019-04-10
CN105452296A (zh) 2016-03-30
LT3708583T (lt) 2022-04-11
AU2014296174B2 (en) 2019-05-02
EP4036118A1 (en) 2022-08-03
IL243409B (en) 2019-10-31
PH12021552742A1 (en) 2022-05-23
KR20230047508A (ko) 2023-04-07
IL243409A0 (en) 2016-03-31
MX2020009223A (es) 2020-10-14
HUE058243T2 (hu) 2022-07-28
TW201906629A (zh) 2019-02-16
ZA201603218B (en) 2019-03-27
PT3708583T (pt) 2022-05-13
US20190175730A1 (en) 2019-06-13
CL2016000221A1 (es) 2016-07-08
RU2019125027A3 (me) 2020-02-28
AU2014296174A1 (en) 2016-01-21
MY184628A (en) 2021-04-10
JP2025118617A (ja) 2025-08-13
PL3027651T3 (pl) 2019-08-30
PL3708583T3 (pl) 2022-06-06
CY1125443T1 (el) 2024-12-13
AU2021245169B2 (en) 2025-02-20
EP3027651A1 (en) 2016-06-08
CN112225810B (zh) 2024-10-29
AU2025203545A1 (en) 2025-06-05
DK3027651T3 (en) 2019-04-15

Similar Documents

Publication Publication Date Title
ZA201808451B (en) Anti-fcrh5 antibodies
ZA201603218B (en) Afucosylated anti-fgfr2iiib antibodies
GB201322583D0 (en) Antibodies
SG11201509361TA (en) Novel antibodies
ZA201601437B (en) Antibodies
IL240404B (en) link means
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
GB201300706D0 (en) Antibody
IL245488A0 (en) Anti- ccl17 antibodies
GB201303507D0 (en) Assays
GB201312226D0 (en) Improved antibodies
GB201318283D0 (en) Antibodies